Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Oxaliplatin in Pancreatic Cancer
NCT00006117Phase 2Unknown
- Sponsor
- GERCOR
- Start
- Sep 1999
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in pancreatic cancer (PC), sponsored by GERCOR. Primary endpoint: Objective Tumor Response Rate. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00006117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006117.